Real-world evidence shows Lumos Diagnostics’ FebriDx cuts antibiotic use and delivers system savings

Lumos Diagnostics (ASX:LDX) has reported encouraging real-world data from the use of its FebriDx point-of-care test across general practice, urgent care, and Acute Respiratory Infection hubs in the UK, showing the device can reduce unnecessary antibiotic use, improve patient satisfaction, and ease health system costs. …